Covid-19 – Day 971: Novavax Recombinant Protein Vaccine

(E) The FDA has just approved the Novavax vaccine, which is now the four Covid-19 vaccine in the U.S after Pfizer, Moderna, and J&J. Novavax’s vaccine leverages a recombinant protein technology similar to the one from Sanofi-GSK that is a decade-old approach, and used in multiple routine vaccinations such as HPV, hepatitis B and influenza.

The vaccine is highly effective, according to the clinical data: two doses were 90% effective at preventing illness from Covid when tested in a study involving about 30,000 adults ages 18 and older.

Following is a short tutorial on Novavx’s recombinant protein technology:

Note: The picture above is the Sars-Cov-2 spike protein – image from the Washinghton post video.

Copyright © 2005-2022 by Serge-Paul Carrasco. All rights reserved.
Contact Us: asvinsider at gmail dot com

Categories: Coronavirus